LDL Cholesterol / Total Cholesterol Ratio

The LDL-C/TC ratio is calculated by dividing your LDL cholesterol (LDL-C) by your total cholesterol (TC) and reporting it as a decimal (e.g., 0.65) or percentage (e.g., 65%). This tells you how much of your total cholesterol “pool” is made up of LDL cholesterol. Total cholesterol is the combined cholesterol carried by multiple lipoproteins in the blood — LDL, VLDL, IDL, HDL, and lipoprotein(a) — while LDL is typically the dominant cholesterol carrier in most people. LDL’s job is to transport cholesterol from the liver to tissues; however, when LDL is present in excess, LDL particles can move into the artery wall, become modified (including oxidation), trigger inflammation, and contribute to plaque formation that narrows arteries and increases risk of heart attack and stroke. The LDL-C/TC ratio therefore gives a “composition snapshot”: a higher ratio (closer to 1.0 or 100%) means a larger share of your cholesterol is sitting in the LDL fraction, while a lower ratio means more of your cholesterol is carried by other particles — often HDL and/or triglyceride-rich particles like VLDL remnants. This ratio is not used as commonly as non-HDL cholesterol or TC/HDL-C ratio, but it can add useful context when interpreted alongside your absolute LDL-C level and the rest of your lipid panel.

The LDL-C/TC ratio can help you understand why your cholesterol profile looks the way it does — especially when you compare it with other lipid markers — however absolute LDL cholesterol remains the primary treatment target in major cardiovascular prevention guidelines, because LDL exposure is strongly and consistently linked to atherosclerotic cardiovascular disease risk. The relationship is described as continuous and “log-linear”: as LDL rises, cardiovascular risk rises progressively, with no clear “safe” threshold where risk disappears.

That said, the ratio matters because it can hint at different underlying metabolic patterns that carry different types of risk. For example, someone can have a lower LDL-C/TC ratio not because their risk is low, but because their total cholesterol includes a larger proportion of cholesterol carried in triglyceride-rich particles (VLDL and remnants) — a pattern often seen in atherogenic dyslipidemia (higher triglycerides, lower HDL, and small dense LDL particles). In that situation, LDL might represent a smaller fraction of total cholesterol (lower ratio), while cardiovascular risk can still be meaningfully elevated due to higher numbers of atherogenic particles, triglyceride-rich remnants, low protective HDL, and more atherogenic LDL particle characteristics. This pattern commonly clusters with insulin resistance, metabolic syndrome, type 2 diabetes, obesity, and broader cardiometabolic dysfunction.

In contrast, a higher LDL-C/TC ratio can be a clue that LDL is dominating the cholesterol profile, which can happen in familial hypercholesterolemia (FH) or other genetic hypercholesterolemias — conditions where LDL particles are elevated due to impaired clearance (often involving LDL receptor pathways) or increased production. In these genetic patterns, LDL may make up an unusually high proportion of total cholesterol, often alongside relatively normal triglycerides and HDL. Because FH involves lifelong exposure to high LDL, lifetime cardiovascular risk can be very high without early identification and management.

Finally, the ratio helps reinforce an important point: LDL-C is crucial, but it isn’t the only informative lipid marker. Research cited in your guide highlights that markers capturing broader atherogenic burden or particle number — such as non-HDL cholesterol, apoB, and ratios that incorporate HDL (e.g., TC/HDL-C) — can sometimes predict events more strongly than LDL-C alone, and can reveal “discordant” risk where LDL-C looks acceptable but overall risk remains higher. That’s why the ratio is best used as context, not a standalone verdict.

Dietary factors
Because the ratio depends on LDL and total cholesterol, anything that raises LDL more than it raises total cholesterol (or shifts cholesterol away from HDL and toward LDL) can increase the ratio. The guide highlights saturated fats and trans fats as the most powerful dietary drivers of higher LDL. Saturated fats (fatty red meat, processed meats, full-fat dairy, butter/cream, some tropical oils, many commercial baked foods) can raise LDL by reducing LDL receptor activity and slowing LDL clearance from blood. Controlled feeding trial data show that replacing saturated fat with polyunsaturated fat lowers LDL in a dose-responsive way. Trans fats (partially hydrogenated oils; many commercial fried foods, some margarines/shortening, some baked goods) have even more adverse effects on lipid profiles.

Dietary cholesterol tends to have a smaller and more variable effect than saturated/trans fats. In controlled analyses, increasing dietary cholesterol raises LDL modestly on average, but the response varies — some people are more “responders,” especially those with dyslipidemia or genetic susceptibility. Guidelines in your text emphasise limiting saturated fat and avoiding trans fats (which often naturally limits dietary cholesterol intake).

On the other side, replacing cholesterol-raising fats with unsaturated fats supports a healthier lipid profile. Monounsaturated fats (extra virgin olive oil, avocados, nuts, seeds) can lower LDL without harming HDL. Polyunsaturated fats, including omega-3 sources (fatty fish; walnuts/flax/chia), can modestly reduce LDL and also improve triglycerides and inflammation — effects that can shift the overall cholesterol distribution. The quality of carbohydrates matters too: swapping saturated fat for refined carbohydrates may lower LDL slightly but can worsen triglycerides and HDL (minimal net benefit), whereas replacing with low-glycaemic whole foods (legumes, vegetables, whole grains, whole fruits) is described as more favourable.

Lifestyle factors
Lifestyle changes that improve insulin sensitivity and body composition can indirectly shift LDL, HDL, and triglyceride-rich particles and therefore influence the ratio. The guide specifically notes that body weight/adiposity and exercise meaningfully affect lipid profiles. Weight loss and consistent activity often improve broader dyslipidemia patterns that influence how cholesterol is distributed across particles.

Related biomarkers and metabolic conditions
The LDL-C/TC ratio can look “better” (lower) in patterns where total cholesterol includes more VLDL/remnant contribution — often seen with higher triglycerides and lower HDL—which is why interpreting the ratio alongside triglycerides, HDL, non-HDL, and metabolic markers is important.

Micronutrient impacts and dietary components
Within your guide, omega-3 intake is highlighted for broader lipid benefits (particularly triglyceride-lowering) and potential anti-inflammatory effects, and dietary strategies that emphasise minimally processed, nutrient-dense foods are described as supportive of healthier lipid patterns overall.

If your results are high

A higher LDL-C/TC ratio means LDL makes up a larger share of your total cholesterol. This can occur with elevated LDL overall and can also raise suspicion for genetic hypercholesterolemia patterns when LDL dominates the profile.

Diet:

• Focus on lowering LDL drivers highlighted in your guide: reduce saturated fats from fatty/processed meats and full-fat dairy and avoid trans fats (partially hydrogenated oils; many commercial fried foods, shortening, some baked goods).

• Replace these with unsaturated fats: extra virgin olive oil, avocado, nuts, seeds, and omega-3 sources.

• If replacing saturated fat, the guide emphasises doing so with polyunsaturated/monounsaturated fats or low-glycaemic whole-food carbohydrates (legumes, vegetables, whole grains, whole fruits), rather than refined starches and added sugars.

Lifestyle
Use consistent exercise and body-composition support strategies described in your guide (diet, exercise and weight management) because these improve lipid patterns and cardiometabolic drivers that sit underneath many elevated LDL profiles.

Supplements
If you and your clinician choose to use supplements described in the guide, omega-3 sources may support broader lipid health (particularly triglycerides) and inflammatory balance, and nutrient-dense dietary patterns support healthier lipid metabolism. (Any supplement use should be individualised and medically supervised, especially if you’re on lipid-lowering therapy or have high baseline risk).

Additional tests:

• Because ratios can miss residual risk or genetic patterns

• the guide supports broader risk characterisation when needed: non-HDL cholesterol

• apoB

• lipoprotein(a)

• potentially advanced lipoprotein particle analysis or coronary artery calcium scoring

• alongside standard lipid panel context. This is especially relevant if the pattern suggests familial hypercholesterolemia or if LDL is high despite good lifestyle habits

If your results are low

A lower LDL-C/TC ratio means less of your total cholesterol is carried by LDL — but this is not always “automatically good,” because it can also occur when more cholesterol sits in triglyceride-rich particles (VLDL/remnants) in atherogenic dyslipidemia patterns.

Diet:

• Keep saturated and trans fats low, and prioritise unsaturated fats and low-glycaemic whole foods as described.

• Pay attention to refined carbohydrate intake if triglycerides are elevated, since this can shift cholesterol into VLDL/remnant pathways.

Lifestyle
Maintain regular exercise and weight management strategies that improve insulin sensitivity and lipid distribution.

Supplements
Omega-3 sources can support triglyceride control and anti-inflammatory balance within the framework described.

Additional tests:

• If triglycerides are elevated or HDL is low

• interpret the ratio alongside TG

• HDL-C

• non-HDL-C

• apoB to clarify true atherogenic burden

1. Lütjohann D, Klör HU, Stellaard F. Measurement of serum low density lipoprotein cholesterol and triglyceride-rich remnant cholesterol as independent predictors of atherosclerotic cardiovascular disease: Possibilities and limitations. Nutrients. 2023;15(9):2202. doi:10.3390/nu15092202.

2. Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: Respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. Journal of the American College of Cardiology. 2009;55(1):35-41. doi:10.1016/j.jacc.2009.07.057.

3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Journal of the American College of Cardiology. 2004;44(3):720-732. doi:10.1016/j.jacc.2004.07.001.

4. Millán J, Pintó X, Muñoz A, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vascular Health and Risk Management. 2009;5:757-765.

5. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298(7):776-785. doi:10.1001/jama.298.7.776.

6. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC health promotion series. Journal of the American College of Cardiology. 2018;72(10):1141-1156. doi:10.1016/j.jacc.2018.06.046.

7. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Reprint of: Impact of lipids on cardiovascular health: JACC health promotion series. Journal of the American College of Cardiology. 2018;72(23 Pt B):2980-2995. doi:10.1016/j.jacc.2018.10.021.

8. Durrington P. Dyslipidaemia. The Lancet. 2003;362(9385):717-731. doi:10.1016/S0140-6736(03)14234-1.

9. Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: Defining the role of low-density lipoprotein heterogeneity in coronary artery disease. Journal of the American College of Cardiology. 2007;50(18):1735-1741. doi:10.1016/j.jacc.2007.07.045.

10. Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review. Journal of the American College of Cardiology. 2020;75(5):525-538. doi:10.1016/j.jacc.2019.11.044.

11. Sniderman AD, Glavinovic T, Thanassoulis G. Key questions about familial hypercholesterolemia: JACC review topic of the week. Journal of the American College of Cardiology. 2022;79(10):1023-1031. doi:10.1016/j.jacc.2022.01.010.

12. Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: A clinical perspective from the National Lipid Association. Journal of Clinical Lipidology. 2023;17(4):428-451. doi:10.1016/j.jacl.2023.05.099.

13. Smith SC, Grundy SM. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. Journal of the American College of Cardiology. 2014;64(6):601-612. doi:10.1016/j.jacc.2014.06.1159.

14. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003.

15. Wilson PWF, Jacobson TA, Martin SS, et al. Lipid measurements in the management of cardiovascular diseases: Practical recommendations—A scientific statement from the National Lipid Association writing group. Journal of Clinical Lipidology. 2021;15(5):629-648. doi:10.1016/j.jacl.2021.09.046.

16. Brummel K, Shah N, Stone NJ. Advanced lipid thinking prior to incorporating advanced lipid testing. The American Journal of Medicine. 2019;132(11):1279-1284. doi:10.1016/j.amjmed.2019.05.034.

17. Kwon YJ, Lee HS, Chang HJ, Koh SB, Lee JW. Association of dietary lipid intake with low-density lipoprotein cholesterol levels: Analysis of two independent population-based studies. European Journal of Nutrition. 2020;59(6):2557-2567. doi:10.1007/s00394-019-02104-3.

18. Clifton PM. Diet, exercise and weight loss and dyslipidaemia. Pathology. 2019;51(2):222-226. doi:10.1016/j.pathol.2018.10.013.

19. Heymsfield SB, Shapses SA. Guidance on energy and macronutrients across the life span. The New England Journal of Medicine. 2024;390(14):1299-1310. doi:10.1056/NEJMra2214275.

20. Vincent MJ, Allen B, Palacios OM, Haber LT, Maki KC. Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol. The American Journal of Clinical Nutrition. 2019;109(1):7-16. doi:10.1093/ajcn/nqy273.